NASDAQ:ABIO ARCA biopharma (ABIO) Stock Price, News & Analysis $3.14 +0.07 (+2.28%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.01▼$3.2950-Day Range$3.07▼$3.8352-Week Range$1.56▼$4.49Volume122,442 shsAverage Volume672,776 shsMarket Capitalization$45.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ARCA biopharma alerts: Email Address ARCA biopharma MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish31.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 4 Articles This WeekInsider TradingAcquiring Shares$1.65 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.21 out of 5 starsMedical Sector921st out of 936 stocksDiagnostic Substances Industry15th out of 15 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for ARCA biopharma.Read more about ARCA biopharma's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted31.17% of the float of ARCA biopharma has been sold short.Short Interest Ratio / Days to CoverARCA biopharma has a short interest ratio ("days to cover") of 38, which indicates bearish sentiment.Change versus previous monthShort interest in ARCA biopharma has recently increased by 1.20%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldARCA biopharma does not currently pay a dividend.Dividend GrowthARCA biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABIO. Previous Next 2.4 News and Social Media Coverage News SentimentARCA biopharma has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ARCA biopharma this week, compared to 1 article on an average week.Search Interest5 people have searched for ABIO on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ARCA biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,650,371.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders30.90% of the stock of ARCA biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.44% of the stock of ARCA biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ARCA biopharma's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ARCA biopharma is -7.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ARCA biopharma is -7.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioARCA biopharma has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ARCA biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About ARCA biopharma Stock (NASDAQ:ABIO)ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.Read More ABIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABIO Stock News HeadlinesJuly 13, 2024 | insidertrades.comARCA biopharma, Inc. (NASDAQ:ABIO) Major Shareholder Henderson Group Plc Janus Purchases 28,326 SharesJuly 23 at 10:41 PM | uk.finance.yahoo.comARCA biopharma Inc (HQ10.MU)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 20, 2024 | msn.comConnor Zilisch wins ARCA race in overtime at Indianapolis Raceway ParkJuly 18, 2024 | americanbankingnews.comStockNews.com Upgrades ARCA biopharma (NASDAQ:ABIO) to "Sell"June 4, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with OrukaMay 14, 2024 | investorplace.com3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty RallyMay 10, 2024 | businesswire.comARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIOJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 1, 2024 | msn.comNoah Gragson Expands 2024 Schedule with NASCAR Xfinity and ARCA RacesApril 30, 2024 | msn.comNoah Gragson adds NASCAR Xfinity, ARCA races to 2024 scheduleApril 28, 2024 | msn.comConnor Zilisch wins ARCA Menards Series race at Dover, first of his careerApril 27, 2024 | msn.comConnor Zilisch reacts to winning first ARCA race as NASCAR career takes next stepApril 27, 2024 | msn.comRed Flags at Dover as Scary Head-On Crash Leaves Amber Balcaen Limping After Attempt to Avoid ARCA Star's Flaming FiascoApril 25, 2024 | investorplace.comABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024April 25, 2024 | globenewswire.comARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate UpdateApril 20, 2024 | money.usnews.comARCA biopharma IncApril 20, 2024 | msn.com18-year-old Jake Finch leads every lap to capture ARCA victory at TalladegaSee More Headlines Receive ABIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/04/2021Today7/26/2024Next Earnings (Estimated)7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:ABIO CUSIPN/A CIK907654 Webarcabio.com Phone(720) 940-2100Fax720-208-9261Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-16.08% Return on Assets-15.51% Debt Debt-to-Equity RatioN/A Current Ratio23.19 Quick Ratio23.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book1.09Miscellaneous Outstanding Shares14,510,000Free Float10,024,000Market Cap$45.56 million OptionableOptionable Beta0.90 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Thomas A. Keuer (Age 65)President, COO & Principal Executive Officer Comp: $400.8kMr. C. Jeffrey Dekker CPA (Age 59)CFO, Treasurer & Company Secretary Comp: $323.07kKey CompetitorsAchieve Life SciencesNASDAQ:ACHVAlpha TeknovaNASDAQ:TKNOVolitionRxNYSE:VNRXImmuCellNASDAQ:ICCCOncoCyteNASDAQ:OCXView All CompetitorsInsidersHenderson Group Plc JanusBought 189,856 shares on 7/24/2024Total: $607,539.20 ($3.20/share)Henderson Group Plc JanusBought 55,463 shares on 7/10/2024Total: $191,901.98 ($3.46/share)Henderson Group Plc JanusBought 47,492 shares on 7/8/2024Total: $164,322.32 ($3.46/share)Henderson Group Plc JanusBought 28,326 shares on 7/5/2024Total: $97,158.18 ($3.43/share)Henderson Group Plc JanusBought 166,042 shares on 7/3/2024Total: $589,449.10 ($3.55/share)View All Insider Transactions ABIO Stock Analysis - Frequently Asked Questions How have ABIO shares performed this year? ARCA biopharma's stock was trading at $1.70 at the beginning of 2024. Since then, ABIO stock has increased by 84.7% and is now trading at $3.14. View the best growth stocks for 2024 here. How were ARCA biopharma's earnings last quarter? ARCA biopharma, Inc. (NASDAQ:ABIO) released its quarterly earnings data on Wednesday, August, 4th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.37) by $2.03. What is Michael R. Bristow's approval rating as ARCA biopharma's CEO? 1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are ARCA biopharma's major shareholders? ARCA biopharma's top institutional investors include Concourse Financial Group Securities Inc.. Insiders that own company stock include Fund Lp Funicular, Henderson Group Plc Janus and Christopher David Ozeroff. View institutional ownership trends. How do I buy shares of ARCA biopharma? Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ARCA biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO) and Gilead Sciences (GILD). This page (NASDAQ:ABIO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARCA biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARCA biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
